Payment overview · 2025
General Payments
$353.47
18 reported records · 11 companies
Healthcare provider profile · identity verified
Lorraine M Mcrae, MD
Allopathic & Osteopathic Physicians|Family Medicine · OKATIE, SC · NPI 1912928912
Verified facts
What the public records show
CMS Open Payments records show Lorraine M Mcrae, MD received $353.47 in general payments during 2025 across 18 reported records.
PFIZER INC. accounted for 23.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $82.76 | 23.4% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $47.88 | 13.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.81 | 13.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $36.72 | 10.4% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $26.92 | 7.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.40 | 6.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.47 | 6.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.26 | 5.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.78 | 4.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.05 | 4.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.42 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $353.47 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $60.99 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $47.88 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $45.81 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $40.53 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $36.72 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.40 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $26.92 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 53 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 51 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 96 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
96 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
96 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 468 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 449 | 140 |
| Atorvastatin Calcium | Atorvastatin Calcium | 401 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 258 | 73 |
| Losartan Potassium | Losartan Potassium | 196 | 55 |
| Lisinopril | Lisinopril | 192 | 55 |
| Metformin Hcl | Metformin Hcl | 180 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 49 |
| Ozempic | Semaglutide | 154 | 24 |
| Furosemide | Furosemide | 152 | 45 |
| Omeprazole | Omeprazole | 152 | 51 |
| Alprazolam | Alprazolam | 139 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 138 | 41 |
| Gabapentin | Gabapentin | 136 | 35 |
| Simvastatin | Simvastatin | 129 | 38 |
| Tramadol Hcl | Tramadol Hcl | 119 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 41 |
| Famotidine | Famotidine | 108 | 41 |
| Carvedilol | Carvedilol | 107 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 107 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 106 | 16 |
| Valsartan | Valsartan | 106 | 34 |
| Potassium Chloride | Potassium Chloride | 103 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 98 | 30 |
| Jardiance | Empagliflozin | 96 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 86 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 32 |
| Ezetimibe | Ezetimibe | 78 | 28 |
| Montelukast Sodium | Montelukast Sodium | 75 | 20 |
| Glimepiride | Glimepiride | 74 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 24 |
| Metformin Hcl Er | Metformin Hcl | 69 | 22 |
| Telmisartan | Telmisartan | 68 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 67 | 21 |
| Allopurinol | Allopurinol | 65 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 60 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 20 |
| Meloxicam | Meloxicam | 58 | 17 |
| Clonazepam | Clonazepam | 56 | 11 |
| Synthroid | Levothyroxine Sodium | 56 | 12 |
| Trazodone Hcl | Trazodone Hcl | 55 | 17 |
| Eliquis | Apixaban | 53 | 12 |
| Farxiga | Dapagliflozin Propanediol | 51 | 17 |
| Trulicity | Dulaglutide | 51 | suppressed |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 15 |
| Spironolactone | Spironolactone | 49 | 17 |
| Atenolol | Atenolol | 48 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 47 | 12 |
| Bupropion Xl | Bupropion Hcl | 45 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 12 |
| Lorazepam | Lorazepam | 43 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 43 | suppressed |
| Repatha Sureclick | Evolocumab | 43 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 43 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 13 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | 11 |
| Glipizide Er | Glipizide | 38 | 12 |
| Valacyclovir | Valacyclovir Hcl | 38 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 13 |
| Sertraline Hcl | Sertraline Hcl | 37 | 16 |
| Pregabalin | Pregabalin | 36 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 11 |
| Glipizide | Glipizide | 34 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 16 |
| Colchicine | Colchicine | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | 11 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 20 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 18 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Fluconazole | Fluconazole | 18 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $353.47 · 18 records | PFIZER INC. | ABRYSVO, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, General - Pain Management, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, PREVNAR 20, Prolastin-C Liquid, QULIPTA, UBRELVY, Veozah, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error